Market Place
Sourcing Support
TG Therapeutics Reports Q3 2024 Results, Raises BRIUMVI® Guidance
04 Nov 2024 //
GLOBENEWSWIRE
TG Therapeutics to Host Q3 2024 Financial Results Call
01 Nov 2024 //
GLOBENEWSWIRE
New data of Briumvi Shows 92% Free From Progression After 5 Years
18 Sep 2024 //
GLOBENEWSWIRE
New Briumvi Data Shows Rapid Infusions Well Tolerated
18 Sep 2024 //
GLOBENEWSWIRE
TG Therapeutics Announces Data Presentations for Multiple Sclerosis
05 Sep 2024 //
GLOBENEWSWIRE
TG Therapeutics Gets IND Clearance For Azer-Cel In Multiple Sclerosis
09 Aug 2024 //
BUSINESSWIRE
TG Therapeutics Reports Q2 2024 Results, Raises BRIUMVI Guidance
06 Aug 2024 //
GLOBENEWSWIRE
HealthCare Royalty and Blue Owl Announce $250M Debt with TG Therapeutics
06 Aug 2024 //
BUSINESSWIRE
TG Therapeutics To Host Q2 2024 Results Call
05 Aug 2024 //
GLOBENEWSWIRE
TG Therapeutics At Goldman Healthcare Conference
06 Jun 2024 //
GLOBENEWSWIRE
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
03 Jun 2024 //
GLOBENEWSWIRE
TG Presents BRIUMVI Data At MS Centers 2024 Meeting
31 May 2024 //
GLOBENEWSWIRE
TG Therapeutics: BRIUMVI Data In Multiple Sclerosis At CMSC 2024
28 May 2024 //
GLOBENEWSWIRE
TG Therapeutics Provides Business Update and Reports Q4
01 May 2024 //
GLOBENEWSWIRE
TG Therapeutics To Host Q1 2024 Financial Results Call
30 Apr 2024 //
GLOBENEWSWIRE
VA Awards TG Therapeutics BRIUMVI Contract For Preferred MS Treatment
18 Apr 2024 //
GLOBENEWSWIRE
TG Therapeutics To Present BRIUMVI MS Data At AAN 2024
18 Apr 2024 //
GLOBENEWSWIRE
TG: BRIUMVI® MS Data At AAN 2024
15 Apr 2024 //
GLOBENEWSWIRE
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI
08 Mar 2024 //
GLOBENEWSWIRE
TG Therapeutics Announces Presentation for BRIUMVI in Multiple Sclerosis
01 Mar 2024 //
GLOBENEWSWIRE
TG Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI
27 Feb 2024 //
GLOBENEWSWIRE
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
26 Feb 2024 //
GLOBENEWSWIRE
TG Therapeutics to Host Conference on Q4 and Year-End 2023 Financial Results
23 Feb 2024 //
GLOBENEWSWIRE
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI
20 Feb 2024 //
GLOBENEWSWIRE
Precision Bio Receives Initial $7.5 Million Cash Payment from TG Therapeutics
12 Feb 2024 //
BUSINESSWIRE
TG Therapeutics Provides Preliminary Fourth Quarter & Full Year 2023 Net Revenue
10 Jan 2024 //
GLOBENEWSWIRE
TG Therapeutics Announces Global License Agreement with Precision BioSciences
09 Jan 2024 //
GLOBENEWSWIRE
TG Therapeutics to Participate in 42nd Annual J.P. Morgan Healthcare Conference
05 Jan 2024 //
GLOBENEWSWIRE
TG Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
27 Nov 2023 //
GLOBENEWSWIRE
TG Therapeutics to Participate in the 5th Annual Guggenheim INI Conference
03 Nov 2023 //
GLOBENEWSWIRE
TG Therapeutics Reports Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results
30 Oct 2023 //
GLOBENEWSWIRE
TG Therapeutics Announces Presentation of Data for BRIUMVI
11 Oct 2023 //
GLOBENEWSWIRE
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI
02 Oct 2023 //
GLOBENEWSWIRE
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
22 Sep 2023 //
GLOBENEWSWIRE
TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Conference
07 Sep 2023 //
GLOBENEWSWIRE
TG Therapeutics Reports Second Quarter 2023 Financial Results
01 Aug 2023 //
GLOBENEWSWIRE
TG Therapeutics and Neuraxpharm Announce Agreement for BRIUMVI
01 Aug 2023 //
GLOBENEWSWIRE
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results
31 Jul 2023 //
GLOBENEWSWIRE
Thinking about buying stock in Virgin Galactic Holdings, TG Therapeutics?
14 Jul 2023 //
PR NEWSWIRE
TG Therapeutics: Too Early To Talk About Blockbuster Briumvi Sales
07 Jul 2023 //
SEEKING ALPHA
TG Therapeutics: A Buy For Its Monster Multiple Sclerosis Agent
15 Jun 2023 //
SEEKING ALPHA
TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
05 Jun 2023 //
GLOBENEWSWIRE
TG Therapeutics Announces Presentation of Data from PhIII Trials of BRIUMVI
02 Jun 2023 //
GLOBENEWSWIRE
TG Therapeutics Announces EC Approval for BRIUMVI for Multiple Sclerosis
02 Jun 2023 //
PRESS RELEASE
TG Therapeutics Announces Data from ULTIMATE I & II Phase 3 Trials of BRIUMVI
31 May 2023 //
GLOBENEWSWIRE
TG Therapeutics to Participate in the Bank of America Securities 2023
04 May 2023 //
GLOBENEWSWIRE
TG Therapeutics Provides Business Update and Reports 1Q 2023
01 May 2023 //
GLOBENEWSWIRE
TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVIÂ
27 Apr 2023 //
GLOBENEWSWIRE
TG Therapeutics Announces Presentation of Data the ULTIMATE I & II Ph 3 Trials
25 Apr 2023 //
GLOBENEWSWIRE
TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI
31 Mar 2023 //
GLOBENEWSWIRE
TG Therapeutics Announces Presentations from ULTIMATE I & II Phase 3 of BRIUMVI
03 Mar 2023 //
GLOBENEWSWIRE
TG Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
TG Announces Presentation of Data from ULTIMATE I & II PIII of BRIUMVI
24 Feb 2023 //
GLOBENEWSWIRE
TG Therapeutics to Host Conference on Q4 Financial Results
24 Feb 2023 //
GLOBENEWSWIRE
TG Therapeutics to Present from ULTIMATE I & II Phase 3 Trials of BRIUMVI
14 Feb 2023 //
GLOBENEWSWIRE
TG Therapeutics Announces Commercial Launch of BRIUMVI for Multiple Sclerosis
26 Jan 2023 //
PRESS RELEASE
Bumpy path forecast for TG Therapeutics’ Briumvi in crowded MS market
13 Jan 2023 //
THE PHARMA LETTER
TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
06 Jan 2023 //
GLOBENEWSWIRE
